Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Average Rating of “Hold” by Analysts

Shares of Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) have earned an average recommendation of “Hold” from the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $36.50.

Several analysts have commented on LKFT shares. Raymond James Financial restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, February 24th. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “sell (d)” rating to a “hold (c)” rating in a report on Thursday, February 26th. Royal Bank Of Canada raised their price objective on shares of Lakefront Biotherapeutics American Depositary Shares from $32.00 to $33.00 and gave the stock a “sector perform” rating in a report on Tuesday, February 24th. UBS Group restated a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a report on Tuesday, February 24th. Finally, Wall Street Zen upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold” rating to a “buy” rating in a report on Saturday, March 28th.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

Institutional investors and hedge funds have recently bought and sold shares of the stock. State of Wyoming bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the second quarter valued at approximately $28,000. Van ECK Associates Corp increased its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% during the fourth quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after purchasing an additional 750 shares in the last quarter. Arax Advisory Partners increased its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% during the fourth quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 1,778 shares in the last quarter. Quadrant Capital Group LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter valued at approximately $134,000. Finally, Squarepoint Ops LLC bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares during the third quarter valued at approximately $211,000. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

Lakefront Biotherapeutics American Depositary Shares Stock Up 3.1%

Shares of Lakefront Biotherapeutics American Depositary Shares stock opened at $28.59 on Friday. Lakefront Biotherapeutics American Depositary Shares has a 52 week low of $24.74 and a 52 week high of $37.78. The business has a 50 day moving average of $30.46 and a 200 day moving average of $31.82. The company has a market cap of $1.88 billion, a PE ratio of -18.21 and a beta of 0.25.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last issued its quarterly earnings data on Sunday, February 15th. The biotechnology company reported $13.92 EPS for the quarter. The company had revenue of $1.06 billion during the quarter. On average, research analysts anticipate that Lakefront Biotherapeutics American Depositary Shares will post -6.97 earnings per share for the current year.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.